Study Details | NCT01124149 - ClinicalTrials. gov Details for study NCT01124149, | ClinicalTrials govThis study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine mesalazine 4 8g day given QD have better long-term outcomes and remain in remission longer compared with subjects who demonstrate only partial remission after acute therapy with MMX mesalamine mesalazine 4 8g day
A Study of Mirikizumab (LY3074828) in Participants With Active Crohns . . . Details for study NCT02891226, | ClinicalTrials govInclusion Criteria: Active Crohn's Disease (CD) as determined by the SES-CD, and participant reported stool frequency and abdominal pain Inadequate response or failure to tolerate at least one of the following: aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg, azathioprine, 6-mercaptopurine, or methotrexate); or
Study Details | NCT03595553 - ClinicalTrials. gov Details for study NCT03595553, | ClinicalTrials govSummit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response rate in subjects treated with ridinilazole as compared to subjects treated with vancomycin A phase 2 proof of concept